PMID- 18949409
OWN - NLM
STAT- MEDLINE
DCOM- 20090105
LR  - 20081024
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 20
IP  - 5
DP  - 2008 Nov
TI  - Potential role of dendritic cell vaccination with MAGE peptides in 
      gastrointestinal carcinomas.
PG  - 1111-6
AB  - Dendritic cells (DCs) loaded with tumor antigens have been emerging as a new 
      strategy in cancer treatment. The MAGE genes are selectively expressed in a 
      variety of cancer tissues such as melanoma or gastrointestinal carcinomas. 
      However, no expression is observed in normal tissues except testis. There are 
      several reports on clinical trials with these immunogenic peptides including MAGE 
      gene-derived, which were shown to be effective for some patients with carcinomas. 
      We previously reported a clinical trial treating gastrointestinal carcinoma 
      patients with immature DC and MAGE peptides via intravenous injection. Autologous 
      DCs were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the 
      patient's HLA haplotype (HLA-A02 or A24). In this study, patients were immunized 
      with mature DCs pulsed with the MAGE-3 peptide four times every 2 weeks via s.c. 
      injection close to the axilla and inguinal lymph nodes. Twenty-eight patients 
      with advanced gastrointestinal carcinoma were treated and no toxic side effects 
      were observed. Peptide-specific CTL responses, improvement in performance status, 
      tumor marker decrease and minor tumor regressions after vaccination were observed 
      in some patients. These results suggested that DC vaccination with the MAGE-3 
      peptide would be safe and can exhibit antitumor effects even in the patients with 
      advanced gastrointestinal carcinoma who were previously treated with chemotherapy 
      or radiation therapy.
FAU - Tanaka, Fumiaki
AU  - Tanaka F
AD  - Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 
      Beppu, Japan.
FAU - Haraguchi, Naotsugu
AU  - Haraguchi N
FAU - Isikawa, Kenji
AU  - Isikawa K
FAU - Inoue, Hiroshi
AU  - Inoue H
FAU - Mori, Masaki
AU  - Mori M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
SB  - IM
MH  - Adenocarcinoma/immunology/*therapy
MH  - Antigens, Neoplasm/*immunology/therapeutic use
MH  - Cancer Vaccines/*therapeutic use
MH  - Dendritic Cells/immunology/*transplantation
MH  - Gastrointestinal Neoplasms/immunology/*therapy
MH  - Humans
MH  - Immunotherapy, Active/*methods
MH  - Neoplasm Proteins/*immunology/therapeutic use
MH  - Peptides/immunology/therapeutic use
EDAT- 2008/10/25 09:00
MHDA- 2009/01/06 09:00
CRDT- 2008/10/25 09:00
PHST- 2008/10/25 09:00 [pubmed]
PHST- 2009/01/06 09:00 [medline]
PHST- 2008/10/25 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2008 Nov;20(5):1111-6.